← back to search

Jieling Miao

Cancer Research And Biostatistics ·
🔎 Find collaborators in Pulmonary and Respiratory Medicine · Organic Chemistry →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Pulmonary and Respiratory Medicine · Organic Chemistry
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Microwave-Assisted Synthesis and Applications, and Synthesis and biological activity.
h-index
17
citations
1,036
works
105
NIH funding
primary concept
Medicine
email

Recent publications

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Journal of Clinical Oncology 2024cited by 17position: middledoi
Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Clinical Cancer Research 2023cited by 19position: middledoi
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
Journal for ImmunoTherapy of Cancer 2021cited by 47position: middledoi
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)
Clinical Lung Cancer 2021cited by 26position: middledoi
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
The Lancet Oncology 2020cited by 122position: middledoi
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Journal of Thoracic Oncology 2019cited by 90position: middledoi
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
JNCI Journal of the National Cancer Institute 2019cited by 76position: middledoi
S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C <i>KRAS</i> mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology 2019cited by 17position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David R. Gandara · Comprehensive Blood & Cancer Center5 papers (2019–2023)Karen Kelly · Thomas Jefferson University5 papers (2019–2023)Philip C. Mack · Tisch Cancer Institute4 papers (2019–2023)Mary W. Redman · Fred Hutch Cancer Center4 papers (2019–2023)William E. Barlow · Cancer Research And Biostatistics2 papers (2019–2024)Jonathan W. Riess · UC Davis Children's Hospital2 papers (2019–2023)Jeffrey D. Bradley · Hospital of the University of Pennsylvania2 papers (2019–2021)Danika L. Lew · Cancer Research And Biostatistics2 papers (2019–2024)Roy S. Herbst · Yale New Haven Hospital2 papers (2019–2021)Vassiliki A. Papadimitrakopoulou · The University of Texas MD Anderson Cancer Center2 papers (2019–2021)Wallace Akerley · University of Utah2 papers (2019–2023)Gabriel N. Hortobágyi · The University of Texas MD Anderson Cancer Center2 papers (2019–2024) · 2 papers (2019–2023)Julie R. Gralow · University of Washington2 papers (2019–2024)Shirish M. Gadgeel · The Barbara Ann Karmanos Cancer Institute2 papers (2019–2023) · 2 papers (2019–2023)Timothy F. Burns · Mayo Clinic in Arizona2 papers (2019–2023)Konstantin H. Dragnev · Dartmouth College2 papers (2019–2023)Katherine Minichiello · Fred Hutch Cancer Center2 papers (2019–2021)Eleftherios P. Mamounas · NRG Oncology1 papers (2024–2024)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Pulmonary and Respiratory Medicine · Organic Chemistry →